00310-4611
                        
                    
                            Imfinzi
                        
                    
                                    Durvalumab
                                
                            
                        
                    
                            INJECTION, SOLUTION
                        
                    
                                    Intravenous
                                
                            
                        
                    
                                     Durvalumab
                                
                                
                                     500.0
                                
                                
                                     mg/10mL
                                
                                
                            
                        
                    
                                     00310-4611-50
                                
                                
                                     1 VIAL in 1 CARTON (0310-4611-50)  / 10 mL in 1 VIAL
                                
                                
                                     May 1, 2017
                                
                                
                                    Immunotherapy
                                
                            
                        
                    
                                    Checkpoint Inhibitor
                                
                            
                        
                    
                                    PD-L1
                                
                            
                        
                    
                            In Use
                        
                     An official website of the United States government
 An official website of the United States government
		 Home
 Home 
                             
                    